Previous 10 | Next 10 |
2023-11-02 22:33:06 ET Grifols, S.A. (GRFS) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Nuria Pascual - IR and Sustainability Officer Thomas Glanzmann - Executive Chairman and CEO Victor Grifols Deu - COO Alfredo Arroyo -...
2023-11-01 12:31:13 ET More on Grifols S.A. Grifols: Cheap For A Reason Seeking Alpha’s Quant Rating on Grifols S.A. Historical earnings data for Grifols S.A. Financial information for Grifols S.A. For further details see: Grifols S.A. Q3 2...
2023-10-19 08:24:17 ET More on Grifols S.A. Grifols: Cheap For A Reason Grifols, S.A. (GRFS) Q2 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Grifols S.A. For further details see: Grifols' unit gets expansion of its contract with th...
2023-09-21 13:56:01 ET Summary Grifols is a Spanish pharmaceutical company focused on blood plasma products, with a strong market position and an attractive growth pathway. The shares have underperformed peers and yielded negative returns over the last five years. We believe t...
2023-07-28 11:07:04 ET Grifols S.A. press release ( NASDAQ: GRFS ): 1H Adj EBITDA of Є655M. Revenue of Є3.23B (+14.8% Y/Y). Total revenue increases to EUR 3,225 million (+14.8%; +13.1% cc1 ) in the first six months of the year, driven by Biopharma F...
2023-07-27 15:45:16 ET Grifols, S.A. (GRFS) Q2 2023 Earnings Conference Call July 27, 2023, 08:30 AM ET Company Participants Nuria Pascual - IR Thomas Glanzmann - our Executive Chairman and CEO Alfredo Arroyo - CFO Victor Grifols Deu - COO Conference Ca...
2023-07-26 16:49:47 ET Grifols S.A. ( NASDAQ: GRFS ) is scheduled to announce Q2 earnings results on Thursday, July 27th, before market open. The consensus EPS Estimate is $0.15 and the consensus Revenue Estimate is $1.82B. For further details see: Grifols S.A. Q...
2023-07-26 11:31:10 ET Major earnings expected before the bell on Thursday include: AbbVie ( ABBV ) Bristol-Myers Squibb ( BMY ) Mastercard ( MA ) McDonald's ( MCD ) Shell ( SHEL ) For further details see: Notable earnings before Thursday'...
2023-07-05 10:56:31 ET Summary Grifols is a promising buy opportunity thanks to its potential to reduce its net debt/EBITDA ratio. The company's focus on deleveraging is showing results and is supported by higher savings and better margins. The plasma collection is also recovering...
2023-05-13 23:14:40 ET Summary I've reviewed Grifols once before and gave you my overall thesis on what I believe to be a solid pharma/biotech company. Investing in Spanish stocks without a dividend and worrying fundamentals is always a "thing" but I'll provide here why I have a s...
News, Short Squeeze, Breakout and More Instantly...
2024-06-12 02:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Grifols 2023 Annual Report on Form 20-F filed with the SEC PR Newswire BARCELONA, Spain , April 19, 2024 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived me...
2024-03-23 01:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...